MuGard, a novel treatment for oral mucositis developed by Access Pharmaceuticals, is now being covered by Tricare, the U.S. military health plan.
Tricare covers more than 9 million active duty service members and retirees of the seven uniformed services, their family members, survivors, and others who are registered in the Defense Enrollment Eligibility Reporting System.
Tricare now provides coverage for MuGard under its various insurance plan options with standard pharmacy benefit copayment, according to Access.
MuGard is a mucoadhesive oral wound rinse and coating for the management of oral mucositis. Up to 40% of all patients receiving chemotherapy and radiotherapy develop moderate to severe mucositis, and almost all patients receiving radiotherapy for head and neck cancer and those undergoing stem cell transplantation develop mucositis.
